1. Introduction {#sec1-dentistry-08-00012}
===============

The risk of relapse in children undergoing craniofacial advancement is very high. Due to the absence of rigid internal fixation systems this risk can increase significantly in those cases that need osteodistraction.

Our standard protocol for treating these cases provides a stabilization period of 120 days after the last activation of the osteodistraction device \[[@B1-dentistry-08-00012],[@B2-dentistry-08-00012],[@B3-dentistry-08-00012]\].

When removal of the distraction device before the end of the treatment is necessary, the reposition of a new fixation system might not be possible. In these cases newly formed bone is immature and relapse of malformation can frequently occur.

In this study we propose the use of an oral device that retains the splanchnocranium in a specific position in order to stabilize facial skeletal structures.

2. Materials and Methods {#sec2-dentistry-08-00012}
========================

We called the oral device "Maxillary Advancement Contention (MAC)" \[[@B4-dentistry-08-00012]\]. (See [Figure 1](#dentistry-08-00012-f001){ref-type="fig"}).

It consists of a functional activator with dental retention. It has an Adam's hook on the last erupted dental elements on both sides and an occlusal plane in acrylic resin to prevent eruption and medialization of the lower primary teeth. A vestibular arch is located on its frontal side in order to stop the advancement of the lower incisors.

The MAC is placed immediately after the removal of the distraction device and left in place for at least 3 months.

In those cases where the distraction device has to be removed before the end of the stabilization, we suggest applying the device every day and removing it only for eating in the first three months. After this time, we recommend wearing it only at night for three more months.

Patients who completed osteodistraction treatment should wear the MAC only at night.

We used MAC in 6 patients, 4 females and 2 males, age ranging from 38--70 months, average 53 months. Two patients were affected by Apert's Syndrome and 4 patients by Crouzon's Syndrome. (See [Table 1](#dentistry-08-00012-t001){ref-type="table"}).

In order to evaluate the relapse of malformation we analyzed the splanchnocranium position on the cephalometric analysis measuring Sella-Nasion-Orbitale (S-N-Or) and Sella-Nasion-A point (S-N-A) angles with Dolphin v. 9.0 (Patterson Dental Supply, St Paul, MN, USA). We considered lateral cephalograms obtained after removal of device (T0) and after 1 year from the end of treatment with MAC (T1).

Patients are informed that in the event of complications, a device will be used to maintain the desired position of the splanchocranium and sign an informed consent before undergoing surgery. This device has the same purpose as the bone stabilizer.

3. Results {#sec3-dentistry-08-00012}
==========

Patient 1 underwent Fronto-orbital advancement with Rigid Internal Fixation stabilization and Osteodistraction of splanchnocranium. In patient 2 and 6 we performed a Le Fort III osteotomy while other patients were treated with Monobloc advancement.

Facial advancement was satisfying for every patient, only the advancement of patient 1 should have been greater in order to reach the appropriate projection. Clinical results were anyway satisfying, so no further surgical procedure was undertaken. (See [Figure 2](#dentistry-08-00012-f002){ref-type="fig"} and [Figure 3](#dentistry-08-00012-f003){ref-type="fig"}).

In four patients the distractor was removed before the planned time due to complications arising during the bone stabilization phase. In these patients the distraction device was removed between the 32nd and the 64th day (average of 44--75 days). In two patients the Osteodistraction Device was removed for infectious complications and in another two for fractures of the underlying bone.

We used MAC in other two patients at the end of the osteodistraction phase to improve bone stability.

The follow up varied between 13 and 52 months, with an average of 32.2 months.

Bone stability was evaluated at the end of treatment and has been shown to be excellent for each patient. In every patient we observed an improvement of maxillary projection and in patients 2, 4, 5, and 6 we detected an advancement of the Orbitale (Or) position. (See [Table 1](#dentistry-08-00012-t001){ref-type="table"}).

4. Discussion {#sec4-dentistry-08-00012}
=============

In children with facial-craniosynostosis functional complications might force anticipation of the time of craniofacial advancement \[[@B4-dentistry-08-00012],[@B5-dentistry-08-00012],[@B6-dentistry-08-00012],[@B7-dentistry-08-00012],[@B8-dentistry-08-00012]\].

In these cases, the early age at surgery increases the risk of anticipated removal of the osteodistraction device thus making the use of MAC appropriate.

We found several advantages in the use of MAC.

With a minimally invasive procedure the MAC system might help to maintain the achieved advancement allowing the stabilization of the newly formed bone.

The MAC keeps the splanchnocranium in the desired position. It can be removed if necessary. The management of the device is very easy and so is its removal and cleaning. These features, along with the reduced size of the device, increased patients' compliance.

The main disadvantage of MAC is due to its manufacturing costs.

The effects of MAC on the temporo-mandibular joint (TMJ) have not been well investigated but due to its limited time of use, it is unlikely that it would cause any problem.

The MAC device can help to stabilize the position of the splanchnocranium but it is useless in maintaining the projection of the fronto-orbital region. In our study only one patient required stabilization of the frontal region with Rigid Internal Fixation, in the other cases we did not detect any relapse of the fronto-orbital bandeau but this can be due to the low number of patients. However, we suppose that the volume expansion of the brain could help to keep the achieved position of the upper third of the face.

The MAC does not provide a fixed retention but a dynamic retention, although it has not shown any negative effect on the formation and stabilization of the bone callus.

According to our clinical observations, the use of MAC must be extended up to six months. This time appears to be enough to allow the formation of a stable bone callus. Longer time of use could be useless and dangerous for the TMJ function and could lead to alteration of the normal development of the lower third of the face or dental eruption.

5. Conclusions {#sec5-dentistry-08-00012}
==============

MAC is an effective aid to help bones to maintain the new position in cases of early removal of the stabilization system in patients treated with craniofacial osteodistraction. The device is easy to produce, not unduly expensive, compliance has been shown to be high, and in addition it gives us the required stability in order not to lose the achieved results.

To conclude our study demonstrates high efficiency for the use of MAC.

However, given the small size of our sample, more accurate studies will have to be carried out.

In particular the effects of the device on the TMJ should be investigated as well as the results on completion of the patient's skeletal growth.

However, treated patients are being continuously followed up during their growth in order to evaluate the effects of the treatment in the long term.
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![Maxillary Advancement Contention (MAC) Device: it is a functional activator with dental retention.](dentistry-08-00012-g001){#dentistry-08-00012-f001}

![First patient, female, 6 years old, affected by Crouzon's Syndrome. Osteodistraction (OD) was removed after 40 days before the established time of osteodistraction for fractures of bone support caused by accidental trauma. Osteodistraction was finished with an advancement of 23 mm. The advancement was interrupted before the normalization of the SNA angle to stop bone advancement. After removal of the OD device, the SNA was 75° and the SNOr was 63°.](dentistry-08-00012-g002){#dentistry-08-00012-f002}

![The same patient after 1 year from the end of treatment with MAC. SNA was 76° and SNOr was 63°.](dentistry-08-00012-g003){#dentistry-08-00012-f003}

dentistry-08-00012-t001_Table 1

###### 

Children treated with Osteodistraction protocol for therapy of craniofacial malformations. In patients 1, 2, 3, 4 the OD (OsteoDistraction) was removed before the end of bone stabilization because of severe complications. The OD was substituted with MAC. Patients 5 and 6 used MAC at the end of the stabilization time to improve the consolidation of callus bone. This table describes the splanchnocranium position before application of MAC and after 1 year.

  PZ       Sex   Age in Months   Pathology   Surgery                                   Advancement in mm   Complication in OD    Stabilization Time in days   Cause of Removal Distraction Device   SNA T0   SNA T1   SNOr T0   SNOr T1   Follow Up (Months)
  -------- ----- --------------- ----------- ----------------------------------------- ------------------- --------------------- ---------------------------- ------------------------------------- -------- -------- --------- --------- --------------------
  1 (SE)   F     70              Crouzon     Fronto-orbital advancement + LeFort III   23                  Stop of advancement   40                           fracture bone support                 75       76       63        63        13
  2 (LC)   F     60              Crouzon     Le Fort III                               22                  no                    64                           infection                             80       81       68        69        22
  3 (AA)   M     49              Crouzon     Monobloc                                  22                  no                    43                           infection                             78       79       70        70        45
  4 (KS)   M     38              Apert       Monobloc                                  20                  no                    32                           fracture bone support                 80       81       72        73        34
  5 (GC)   F     49              Crouzon     Monobloc                                  25                  no                    120                          stabilization completed               80       81       68        70        52
  6 (CF)   F     52              Apert       Le Fort III                               21                  no                    120                          stabilization completed               81       82       70        71        48
